LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

Search

Bio-Techne Corp

Geschlossen

Branche Gesundheitswesen

80.52 2.4

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

78.49

Max

80.92

Schlüsselkennzahlen

By Trading Economics

Einkommen

22M

49M

Verkäufe

303B

303B

KGV

Branchendurchschnitt

50.64

79.786

EPS

0.48

Gewinnspanne

0.016

EBITDA

8.2M

92M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+4.23 upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Aug. 2024

Nächste Dividendenausschüttung

30. Aug. 2024

Nächstes Ex-Dividendendatum

15. Aug. 2024

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1B

12B

Vorheriger Eröffnungskurs

78.12

Vorheriger Schlusskurs

80.52

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Bio-Techne Corp Chart

Ähnliche Nachrichten

26. Juli 2024, 22:06 UTC

Wichtige Markttreiber

vTv Therapeutics Shares Tumble After FDA Pauses Diabetes-Treatment Study

26. Juli 2024, 19:26 UTC

Ergebnisse

Trending: 3M Shares Surge On Earnings

26. Juli 2024, 17:40 UTC

Ergebnisse

Merck KGaA FY24 Outlook Improves After Strong Second Quarter

26. Juli 2024, 17:21 UTC

Wichtige Markttreiber

Aon Shares Rise Following Better-Than-Expected 2Q Results

26. Juli 2024, 22:40 UTC

Akquisitionen, Fusionen, Übernahmen

Burger King Parent Company and More Stocks See Action From Activist Investors -- Barrons.com

26. Juli 2024, 21:27 UTC

Market Talk

Consumers Are Skipping Starbucks' Half-Priced Drinks -- Market Talk

26. Juli 2024, 20:54 UTC

Ergebnisse

3M Stock Had Its Best Day Ever. The New CEO Started With a Bang. -- Barrons.com

26. Juli 2024, 20:50 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

26. Juli 2024, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

26. Juli 2024, 20:50 UTC

Market Talk
Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

26. Juli 2024, 20:50 UTC

Top News

Dow Industrials Jump to Cap Volatile Week -- WSJ

26. Juli 2024, 20:27 UTC

Akquisitionen, Fusionen, Übernahmen

Blackstone Real Estate, MRP Group Announce Extension of 100% Cash Tender Offer for Terrafina

26. Juli 2024, 20:16 UTC

Ergebnisse

These Stocks Moved the Most Today: DexCom, 3M, Nvidia, Bristol Myers, Coursera, Biogen, Charter, Deckers, and More -- Barrons.com

26. Juli 2024, 19:28 UTC

Market Talk

U.S. Natural Gas Futures Fall for Second Straight Week -- Market Talk

26. Juli 2024, 19:15 UTC

Market Talk

Oil Futures Close Lower for a Third Straight Week -- Market Talk

26. Juli 2024, 19:00 UTC

Market Talk

Nike Must Restore Exclusivity to Jumpstart Footwear Brand -- Market Talk

26. Juli 2024, 18:29 UTC

Market Talk

Gold Shares Attempt To Reverse Losses -- Market Talk

26. Juli 2024, 17:36 UTC

Market Talk

U.S. Oil Rig Count Rises By Five To 482 -- Market Talk

26. Juli 2024, 16:57 UTC

Ergebnisse

Merck KGaA to Post Full 2Q Figures as Scheduled on Aug 1

26. Juli 2024, 16:55 UTC

Ergebnisse

Merck KGaA Sees 2024 EBITDA Before One-Time Items of Approx. EUR5.8B to EUR6.4B

26. Juli 2024, 16:54 UTC

Ergebnisse

Merck KGaA Sees 2024 Net Sales of Approx. EUR20.7B to EUR22.1B

26. Juli 2024, 16:54 UTC

Ergebnisse

Merck KGaA: Performance of Life Science Is Within Expectations

26. Juli 2024, 16:54 UTC

Ergebnisse

Merck KGaA: Main Driver Is Very Strong Oper Performance of Healthcare, Electronics Compared to Consensus

26. Juli 2024, 16:53 UTC

Ergebnisse

Merck KGaA 2Q EBITDA Before One-Time Items EUR1.51B

26. Juli 2024, 16:52 UTC

Ergebnisse

Merck KGaA 2Q Net Sales EUR5.35B

26. Juli 2024, 16:51 UTC

Ergebnisse

Intel's AI Chip Story 'Feels Mostly MIA,' Says Analyst -- Barrons.com

26. Juli 2024, 16:51 UTC

Ergebnisse

Merck KGaA Raised Guidance for Fiscal 2024

26. Juli 2024, 16:20 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

26. Juli 2024, 16:20 UTC

Market Talk
Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

26. Juli 2024, 16:20 UTC

Market Talk
Ergebnisse

Basic Materials Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Bio-Techne Corp Prognose

Kursziel

By TipRanks

4.23% Vorteil

12-Monats-Prognose

Durchschnitt 82 USD  4.23%

Hoch 95 USD

Tief 65 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Bio-Techne Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

8 ratings

5

Buy

3

Halten

0

Sell

Technischer Score

By Trading Central

77.77 / 80.515Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Very Strong Bullish Evidence

Langfristig

Neutral Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Bio-Techne Corp

Bio-Techne Corporation is a developer, manufacturer, and seller of life science reagents, instruments and services for the research, diagnostics, and bioprocessing markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits.